To determine whether ASA influences MM growth in vivo, a xenograft model was established by injecting severe-combined immunodeficient (SCID) mice with luciferase-expressing HMGB1-secreting human MM cell line REN (REN/luc) intraperitoneally.7 ASA was given by oral gavage at the doses of 25 mg/kg per day, which according to previous studies should be equivalent to 80–110 mg per day in humans.19 ASA treatment was initiated 4 days after injecting REN/luc cells, which is when the tumors became detectable by IVIS imaging. This evidence concerns the gene HMGB1 and Miyoshi myopathy.